Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, CollPlant Biotechnologies Ltd reported revenue of $2M, up 360.4% year over year. Operating margin was -484.3% and net margin -484.6%, on a free-cash-flow margin of -398.4% with capital expenditure at 1.2% of revenue. Every figure is computed directly from CLGN's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $2M | -484.3% | -484.6% |
| FY2024 | $1M | -3349.7% | -3225.0% |
| FY2023 | $11M | -68.5% | -64.0% |
| FY2022 | $0M | -5718.1% | -5660.5% |
| FY2021 | $16M | 0.4% | 1.5% |
How does CLGN compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.